exatecan mesylate
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Jun 1, 1999 → Aug 1, 2001
NCT ID
NCT00004045About exatecan mesylate
exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00004045. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00055952 | Phase 2 | Completed |
| NCT00055939 | Phase 2 | Completed |
| NCT00017212 | Phase 2 | Completed |
| NCT00005938 | Phase 2 | Completed |
| NCT00004866 | Phase 2 | Completed |
| NCT00004108 | Phase 2 | Completed |
| NCT00004060 | Phase 2 | Completed |
| NCT00004046 | Phase 2 | Completed |
| NCT00003951 | Phase 2 | Completed |
| NCT00004045 | Phase 2 | Completed |
| NCT00004047 | Phase 1 | Completed |
Competing Products
20 competing products in Prostate Cancer